Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(33%)
Terminated
1(17%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Terminated(1)
Other(1)

Detailed Status

Not yet recruiting2
Recruiting2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 33 (50.0%)

Trials by Status

not_yet_recruiting233%
terminated117%
unknown117%
recruiting233%

Recent Activity

2 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

NCT07469241
recruitingphase_3

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

NCT07154069
not_yet_recruitingphase_3

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

NCT06957938
recruitingphase_2

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

NCT06455410
terminatedphase_3

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

NCT03745222
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07469241Phase 2

Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

Not Yet Recruiting
NCT07154069Phase 3

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

Recruiting
NCT06957938Phase 3

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

Not Yet Recruiting
NCT06455410Phase 2

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

Recruiting
NCT03745222Phase 3

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Terminated
NCT03588494Phase 2

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

Unknown

All 6 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
6